ATE429486T1 - Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten - Google Patents

Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten

Info

Publication number
ATE429486T1
ATE429486T1 AT02762780T AT02762780T ATE429486T1 AT E429486 T1 ATE429486 T1 AT E429486T1 AT 02762780 T AT02762780 T AT 02762780T AT 02762780 T AT02762780 T AT 02762780T AT E429486 T1 ATE429486 T1 AT E429486T1
Authority
AT
Austria
Prior art keywords
cell
antigen
growth factor
lymphocytes
binding
Prior art date
Application number
AT02762780T
Other languages
English (en)
Inventor
Hiroaki Sagawa
Mitsuko Ideno
Ikunoshin Kato
Original Assignee
Takara Bio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takara Bio Inc filed Critical Takara Bio Inc
Application granted granted Critical
Publication of ATE429486T1 publication Critical patent/ATE429486T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4267—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
    • A61K40/4268—MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/12—Hepatocyte growth factor [HGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/58—Adhesion molecules, e.g. ICAM, VCAM, CD18 (ligand), CD11 (ligand), CD49 (ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/599—Cell markers; Cell surface determinants with CD designations not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/90—Polysaccharides
    • C12N2501/905—Hyaluronic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT02762780T 2001-08-15 2002-08-15 Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten ATE429486T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2001246747 2001-08-15
JP2001376966 2001-12-11
JP2002084428 2002-03-25
PCT/JP2002/008298 WO2003016511A1 (fr) 2001-08-15 2002-08-15 Procede permettant une culture etendue de lymphocytes t cytotoxiques specifiques d'un antigene

Publications (1)

Publication Number Publication Date
ATE429486T1 true ATE429486T1 (de) 2009-05-15

Family

ID=27347333

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02762780T ATE429486T1 (de) 2001-08-15 2002-08-15 Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten

Country Status (9)

Country Link
US (1) US7910368B2 (de)
EP (2) EP2070542A3 (de)
JP (3) JP4949607B2 (de)
KR (2) KR100888915B1 (de)
CN (2) CN101633907B (de)
AT (1) ATE429486T1 (de)
DE (1) DE60232083D1 (de)
TW (3) TW200718784A (de)
WO (1) WO2003016511A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7816134B2 (en) * 2000-08-16 2010-10-19 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic T cells
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
EA010434B1 (ru) * 2002-03-25 2008-08-29 Такара Био Инк. Способ получения цитотоксических лимфоцитов
CN1839202B (zh) * 2003-08-22 2012-07-18 宝生物工程株式会社 细胞毒性淋巴细胞的制备方法
WO2007020880A1 (ja) 2005-08-17 2007-02-22 Takara Bio Inc. リンパ球の製造方法
JP4741906B2 (ja) * 2005-08-31 2011-08-10 タカラバイオ株式会社 リンパ球の製造方法
KR101408565B1 (ko) * 2005-09-30 2014-06-17 다카라 바이오 가부시키가이샤 Ｔ 세포 집단의 제조 방법
KR20090024782A (ko) 2006-06-09 2009-03-09 다카라 바이오 가부시키가이샤 림프구의 제조 방법
JPWO2008111430A1 (ja) * 2007-03-09 2010-06-24 タカラバイオ株式会社 γδＴ細胞集団の製造方法
JPWO2008143014A1 (ja) * 2007-05-11 2010-08-05 タカラバイオ株式会社 がん治療剤
WO2009119793A1 (ja) 2008-03-27 2009-10-01 タカラバイオ株式会社 遺伝子導入細胞の製造方法
EP2236517A1 (de) 2009-03-31 2010-10-06 Takara Bio, Inc. Monoklonaler Anti-Fibronektinfragment-Antikörper
JPWO2011024791A1 (ja) 2009-08-25 2013-01-31 タカラバイオ株式会社 レチノイン酸存在下でのｔ細胞集団の製造方法
KR101110866B1 (ko) * 2009-12-29 2012-02-20 재단법인 포항산업과학연구원 몰드 동판 가공 장치
JP5805089B2 (ja) * 2010-08-10 2015-11-04 タカラバイオ株式会社 細胞集団の製造方法
WO2012139040A1 (en) * 2011-04-07 2012-10-11 The Scripps Research Institute High-throughput screening for compounds modulating expression of cellular macromolecules
CN103013914B (zh) * 2012-12-13 2014-12-03 吉林省拓华生物科技有限公司 体外培养杀伤性t细胞的方法
US20150079626A1 (en) * 2013-03-19 2015-03-19 Lsip, Llc Method of obtaining a cell population containing cancer stem cells
WO2015174928A1 (en) 2014-05-15 2015-11-19 National University Of Singapore Modified natural killer cells and uses thereof
JP7256749B2 (ja) 2017-03-27 2023-04-12 ナショナル ユニヴァーシティー オブ シンガポール ナチュラルキラー細胞免疫療法における切断されたｎｋｇ２ｄキメラ受容体及びその使用
RU2019128544A (ru) 2017-03-27 2021-04-28 Нэшнл Юниверсити Оф Сингапур Линии стимулирующих клеток для ex vivo размножения и активации клеток-натуральных киллеров
AU2019219454A1 (en) 2018-02-09 2020-08-27 National University Of Singapore Activating chimeric receptors and uses thereof in natural killer cell immunotherapy
SG11202008976YA (en) 2018-04-02 2020-10-29 Nat Univ Singapore Neutralization of human cytokines with membrane-bound anti-cytokine non-signaling binders expressed in immune cells
BR112021002365A2 (pt) * 2018-08-10 2021-05-11 Kyoto University métodos para produzir uma célula cd3-positiva, para prevenção ou tratamento de um tumor e para manter uma célula cd3-positiva como uma célula cd3-positiva cd197-positiva, célula cd3-positiva, método de cultura para expansão de uma célula cd3-positiva, kits para cultura de expansão de uma célula cd3-positiva e para manter uma célula cd3-positiva como uma célula cd3-positiva cd197-positiva, receptor de antígeno quimérico, ácido nucleico, vetor de expressão do receptor de antígeno quimérico, célula expressando o receptor de antígeno quimérico, medicamento, agente para eliminar uma célula, e, uso da célula.
WO2020044239A1 (en) 2018-08-29 2020-03-05 National University Of Singapore A method to specifically stimulate survival and expansion of genetically-modified immune cells
BR112021017537A2 (pt) 2019-03-05 2021-12-14 Nkarta Inc Receptores de antígeno quimérico dirigidos a cd19 e usos dos mesmos em imunoterapia

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8516421D0 (en) 1985-06-28 1985-07-31 Biotechnology Interface Ltd Fibronectins
US5019646A (en) 1987-08-25 1991-05-28 Regents Of The University Of Minnesota Polypeptides with fibronectin activity
US5057423A (en) 1987-12-18 1991-10-15 University Of Pittsburgh Method for the preparation of pure LAK-active lymphocytes
JP2561131B2 (ja) 1988-06-30 1996-12-04 寳酒造株式会社 細胞接着活性ポリペプチド
GB8909916D0 (en) 1989-04-29 1989-06-14 Delta Biotechnology Ltd Polypeptides
US5198423A (en) 1989-05-26 1993-03-30 Takara Shuzo Co., Ltd. Functional polypeptide containing a cell binding domain and a heparin binding domain of fibronectin
US5188959A (en) 1989-09-28 1993-02-23 Trustees Of Tufts College Extracellular matrix protein adherent t cells
JP3104178B2 (ja) 1990-03-30 2000-10-30 寶酒造株式会社 機能性ポリペプチド
JPH04297494A (ja) 1991-03-26 1992-10-21 Fuji Photo Film Co Ltd ペプチド誘導体とその用途
JP2729712B2 (ja) 1991-04-23 1998-03-18 寳酒造株式会社 機能性ポリペプチド
JPH07102131B2 (ja) * 1991-07-15 1995-11-08 日本石油株式会社 ヒトリンパ球の癌細胞に対する傷害活性を高める方法
JPH06306096A (ja) 1993-02-26 1994-11-01 Fuji Photo Film Co Ltd ペプチド誘導体及びその用途
GB9315810D0 (en) 1993-07-30 1993-09-15 Univ London Stabilised materials
DE4336399A1 (de) 1993-10-26 1995-04-27 Augustinus Dr Med Bader Verfahren zur Verbesserung der Matrixbedingungen bipolar adhärierter Hepatozyten und zur Herstellung eines entsprechend konfigurierten Zellkulturkits
US6821778B1 (en) * 1993-12-01 2004-11-23 The Board Of Trustees Of Leland Stanford Junior University Methods for using dendritic cells to activate gamma/delta-T cell receptor-positive T cells
DE4412794A1 (de) 1994-04-14 1995-12-14 Univ Ludwigs Albert Verfahren zur Herstellung von dendritischen Zellen, so erhaltene Zellen und Behälter zur Durchführung dieses Verfahrens
GB9413029D0 (en) 1994-06-29 1994-08-17 Common Services Agency Stem cell immobilisation
CN1116549A (zh) * 1994-08-09 1996-02-14 中国医学科学院肿瘤研究所 新型高亲和性肿瘤杀伤细胞(t-ak细胞)制剂
US5827642A (en) * 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
US5824547A (en) 1994-11-29 1998-10-20 Takara Shuzo Co., Ltd. Method for production of transfected cells
EP0797450A4 (de) * 1994-12-01 2000-02-02 New England Deaconess Hospital In vitro t-lymphopoiese system
CA2220226C (en) 1995-05-04 2008-10-21 Carl H. June Improved methods for transfecting t cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
JPH0925299A (ja) 1995-07-13 1997-01-28 Sumitomo Electric Ind Ltd Ｃｄ４４リガンド
JP2001520509A (ja) * 1995-07-25 2001-10-30 セルセラピー・インコーポレイテツド 自己免疫細胞療法：細胞組成物、方法およびヒト疾患の治療への応用
ATE325533T1 (de) * 1995-09-29 2006-06-15 Univ Indiana Res & Tech Corp Verfahren zum verbesserten virusvermittelten dns- transfer unter verwendung von molekülen mit virus-und zellbindenden domänen
KR100353115B1 (ko) 1995-11-13 2003-01-06 다카라츠죠 가부시키가이샤 레트로바이러스를사용한표적세포내로의유전자도입방법
US6734014B1 (en) * 1996-02-08 2004-05-11 The United States Of America As Represented By The Department Of Health And Human Services Methods and compositions for transforming dendritic cells and activating T cells
JP2002516562A (ja) * 1996-03-04 2002-06-04 ターゲティッド ジェネティックス コーポレイション Ｔリンパ球のインビトロ増殖のための改変された迅速な拡大方法（「改変ｒｅｍ」）
CA2247131A1 (en) * 1996-03-04 1997-09-12 Targeted Genetics Corporation Modified rapid expansion methods ("modified-rem") for in vitro propagation of t lymphocytes
CA2267288A1 (en) 1996-09-23 1998-03-26 Ontogeny, Inc. Hematopoietic stem cells and methods for generating such cells
CA2278189A1 (en) 1997-01-31 1998-08-06 Epimmune, Inc. Peptides and peptide-loaded antigen presenting cells for the activation of ctl
AU2010699A (en) * 1997-12-24 1999-07-19 Corixa Corporation Compounds for immunotherapy and diagnosis of breast cancer and methods for theiruse
ATE376840T1 (de) 1999-03-23 2007-11-15 Takara Bio Inc Gentherapeutika
JP3904374B2 (ja) 2000-02-29 2007-04-11 独立行政法人科学技術振興機構 キラー活性を増強したリンパ球
US7816134B2 (en) * 2000-08-16 2010-10-19 Takara Bio Inc. Method of extensive culture of antigen-specific cytotoxic T cells
CN1314414A (zh) * 2001-03-16 2001-09-26 中国人民解放军第四军医大学 一种新的分子量为140kDa的活化T细胞表面抗原
TW200718784A (en) 2001-08-15 2007-05-16 Takara Bio Inc Method of extended culture for antigen-specific cytotoxic T lumphocytes
EA010434B1 (ru) 2002-03-25 2008-08-29 Такара Био Инк. Способ получения цитотоксических лимфоцитов

Also Published As

Publication number Publication date
JP2008278892A (ja) 2008-11-20
EP2070542A2 (de) 2009-06-17
KR20040030093A (ko) 2004-04-08
EP1424387B1 (de) 2009-04-22
CN101633907B (zh) 2012-09-05
EP1424387A1 (de) 2004-06-02
JPWO2003016511A1 (ja) 2004-12-02
CN100510060C (zh) 2009-07-08
JP4472764B2 (ja) 2010-06-02
WO2003016511A1 (fr) 2003-02-27
DE60232083D1 (de) 2009-06-04
JP4332573B2 (ja) 2009-09-16
KR100858857B1 (ko) 2008-09-17
TW200718784A (en) 2007-05-16
TW200626725A (en) 2006-08-01
JP4949607B2 (ja) 2012-06-13
JP2008035864A (ja) 2008-02-21
CN1543501A (zh) 2004-11-03
TWI315740B (de) 2009-10-11
TWI311586B (en) 2009-07-01
EP2070542A3 (de) 2010-01-06
CN101633907A (zh) 2010-01-27
EP1424387A4 (de) 2005-10-12
US20050042208A1 (en) 2005-02-24
KR20070122579A (ko) 2007-12-31
KR100888915B1 (ko) 2009-03-16
US7910368B2 (en) 2011-03-22

Similar Documents

Publication Publication Date Title
ATE429486T1 (de) Expansionskulturverfahren für antigenspezifische zytotoxische t-lymphozyten
DE60034566D1 (de) Peptidakzeptor ligationsverfahren
ATE346938T1 (de) Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
EA200800996A1 (ru) Способ получения т-клеточной популяции
SG152273A1 (en) Pdx1 expressing endoderm
ATE314395T1 (de) Humanisierte antikörper und verfahren zu ihrer herstellung
DK1456346T3 (da) Nyt inducerbart genekspressionssystem baseret på ecdysonreceptor/invertebrat-retinoid-x-receptor
DE60213803D1 (en) Happier mapping
ATE278785T1 (de) Neues verfahren zur gewinnung und reinigung von fusionsproteinen
AU2002329256A1 (en) Methods of rna and protein synthesis
ATE506381T1 (de) Halogen-substituiertes katalysatorsystem zur olefinpolymerisation
EA200600459A1 (ru) Способ получения цитотоксических лимфоцитов
ATE344321T1 (de) Verfahren zur aufreinigung von bakterienzellen und zellbestandteilen
ATE555194T1 (de) Methode zur herstellung von proliferierenden und differenzierenden zelllinien
WO1999050459A3 (en) High throughput in vitro screening assays for transcription modulators
HUP0204421A2 (en) Chemically-modified supports and supported catalyst systems prepared therefrom
DE60225312D1 (de) Samenspezifische 7s-alpha-promoter zur expression von genen in pflanzen
ATE416257T1 (de) Promotoren für wachstums-differenzierungsfaktoren und deren verwendung
ATE505535T1 (de) Verfahren zur herstellung stabiler b-lymphozyten
DE60136558D1 (de) Verfahren zur kultivierung humaner chondrozyten
DK1095032T3 (da) Hidtil ukendte fluorescerende CYP2D-assayreagenser
EA200000483A1 (ru) Способ и устройство для выращивания (концентрирования) и исследования микробиологических проб
CY1109583T1 (el) Κυτοκινες θηλαστικων, αντιστοιχα αντιδραστηρια
DK1238057T3 (da) Fremgangsmåde til produktion af vedhæftende dyreceller
DE69930294D1 (de) Minimale promotoren und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties